Atlas Trials

Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)

Clinical trial NCT07161037 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT07161037
Sponsor
Vertex Pharmaceuticals Incorporated
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Start date
2025-11-19
Primary completion
2027-07-22
Enrollment
26

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.